Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics

Area of Science:

• Virology
• Molecular Biology
• Gene Editing Technologies

Background:

• Hepatitis B virus (HBV) infection is a major global health concern, causing chronic hepatitis, cirrhosis, and liver cancer.
• Viral persistence is maintained by covalently closed circular DNA (cccDNA) and integrated HBV DNA.
• Current treatments have limitations in eradicating the virus.

Purpose of the Study:

• To provide a comprehensive overview of CRISPR/Cas technology applications in inhibiting HBV.
• To highlight recent advancements, particularly non-double-strand (non-DSB) break approaches.
• To discuss the broader utility of CRISPR/Cas in HBV diagnosis and cccDNA research.

Main Methods:

• Review of current literature on CRISPR/Cas systems targeting HBV.
• Analysis of strategies involving direct targeting of cccDNA and integrated HBV DNA.
• Exploration of indirect inhibition methods, including RNA degradation and host protein targeting.

Main Results:

• CRISPR/Cas systems show promise in inhibiting HBV by targeting viral genetic material.
• Non-DSB CRISPR/Cas approaches offer potential for safer and more effective viral inhibition.
• CRISPR/Cas technology is also valuable for HBV diagnostics and understanding cccDNA biology.

Conclusions:

• CRISPR/Cas technology presents a versatile and powerful toolkit for combating HBV infection.
• Novel non-DSB CRISPR/Cas strategies are emerging as key therapeutic avenues.
• The diverse applications of CRISPR/Cas extend beyond direct inhibition to diagnostics and fundamental research in HBV.